The main objective of this PPG is to identify novel influenza immunogens based on conserved regions of the HA and immunization protocols resulting in broad protective humoral immunity against multiple strains and subtypes of influenza A viruses. It has been known for many years that antibodies directed against specific regions of the HA protein of influenza virus have potent virus neutralizing activities, and play an important role in protection against infection after natural exposure or vaccination. Also for many years it was assumed that protection induced by HA antibodies was highly specific for single virus strains, as, in general, virus infection and/or vaccination only protect against infection with the same strain of influenza virus. This established dogma in the influenza virus field has been shattered by the recent discovery and generation of multiple monoclonal antibodies directed against conserved regions in the HA molecule that have broad neutralizing activities. In general, this type of cross-reacting antibodies is present only at low frequencies in immunized individuals, most likely due to the immunodominance of strain specific epitopes. Our collaborators in this PPG, Peter Palese (Project 1) and Patrick Wilson (Monoclonal Antibody Technology Core) have developed techniques for the generation and identification of these broadly neutralizing antibodies in mice and in humans. In order to take advantage of these breakthroughs we will, in collaboration with Project 1 and the Technology Core, investigate the potency of the different antibodies against different influenza virus strains in a mouse model (Aim 1).
Aim 1 studies will inform to Project 1 on specific antibodies with potent and broad efficacy in vivo for further characterization by Project 1 on epitope specificity. In addition.
Aim 1 will identify specific antibodies with a good potential to be developed as therapeutic tools for the treatment of severe influenza. Furthermore, to explore vaccination strategies based on HA-based immunogens recognized by broadly neutralizing monoclonal antibodies, we will use the immunogens developed by Project 1 (PI: Palese) and immunization protocols developed by Project 2 (PI: Ahmed) to investigate the ability of these immunogens to generate protective immune responses in two animal models, the mouse and the ferret (Aim 2), and the mechanism of antibody-mediated neutralization and protection (Aim 3). The information generated by Aims 2 and 3 will provide the basis for potential further development into novel

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI097092-02
Application #
8528833
Study Section
Special Emphasis Panel (ZAI1-RB-M)
Project Start
Project End
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
2
Fiscal Year
2013
Total Cost
$302,178
Indirect Cost
$69,557
Name
Icahn School of Medicine at Mount Sinai
Department
Type
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Guo, Hailong; Baker, Steven F; Martínez-Sobrido, Luis et al. (2014) Induction of CD8 T cell heterologous protection by a single dose of single-cycle infectious influenza virus. J Virol 88:12006-16
Krammer, Florian; Margine, Irina; Hai, Rong et al. (2014) H3 stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge. J Virol 88:2340-3
Krammer, Florian; Palese, Peter (2014) Universal influenza virus vaccines: need for clinical trials. Nat Immunol 15:3-5
Krammer, Florian; Hai, Rong; Yondola, Mark et al. (2014) Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets. J Virol 88:3432-42
Schotsaert, Michael; García-Sastre, Adolfo (2014) Influenza vaccines: a moving interdisciplinary field. Viruses 6:3809-26
Miller, Matthew S; Palese, Peter (2014) Peering into the crystal ball: influenza pandemics and vaccine efficacy. Cell 157:294-9
DiLillo, David J; Tan, Gene S; Palese, Peter et al. (2014) Broadly neutralizing hemagglutinin stalk-specific antibodies require Fc?R interactions for protection against influenza virus in vivo. Nat Med 20:143-51
Heaton, Nicholas S; Langlois, Ryan A; Sachs, David et al. (2014) Long-term survival of influenza virus infected club cells drives immunopathology. J Exp Med 211:1707-14
Cowan, Michelle; Chon, W James; Desai, Amishi et al. (2014) Impact of immunosuppression on recall immune responses to influenza vaccination in stable renal transplant recipients. Transplantation 97:846-53
Krammer, Florian; Albrecht, Randy A; Tan, Gene S et al. (2014) Divergent H7 immunogens offer protection from H7N9 virus challenge. J Virol 88:3976-85

Showing the most recent 10 out of 22 publications